United Therapeutics Corporation Cost of Revenue
United Therapeutics Corporation (UTHR) reported Cost of Revenue of $99.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- United Therapeutics Corporation cost of goods and services sold for the quarter ending 2026-06-30 was $99.50M, a 13.58% increase year-over-year.
- United Therapeutics Corporation cost of goods and services sold for the quarter ending 2026-03-31 was $133.40M, a 44.22% increase year-over-year.
- United Therapeutics Corporation cost of goods and services sold for the quarter ending 2025-12-31 was $103.40M, a 36.23% increase year-over-year.
- United Therapeutics Corporation cost of goods and services sold for the quarter ending 2025-09-30 was $100.90M, a 21.42% increase year-over-year.
- United Therapeutics Corporation cost of goods and services sold for fiscal 2025 was $384.40M, a 24.12% increase from fiscal 2024.
- United Therapeutics Corporation cost of goods and services sold for fiscal 2024 was $309.70M, a 20.27% increase from fiscal 2023.
- United Therapeutics Corporation cost of goods and services sold for fiscal 2023 was $257.50M, a 69.85% increase from fiscal 2022.
- United Therapeutics Corporation cost of goods and services sold for fiscal 2022 was $151.60M, a 23.76% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $99.50M 10-Q · filed 2026-08-05 | $232.90M 10-Q · filed 2026-08-05 | $336.30M derived: sum of 3 quarters · filed 2026-08-05 | $437.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $133.40M 10-Q · filed 2026-05-06 | $236.80M derived: sum of 2 quarters · filed 2026-05-06 | $337.70M derived: sum of 3 quarters · filed 2026-05-06 | $425.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $103.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $204.30M derived: sum of 2 quarters · filed 2026-02-25 | $291.90M derived: sum of 3 quarters · filed 2026-08-05 | $384.40M 10-K · filed 2026-02-25 |
| 2025-09-30 | $100.90M 10-Q · filed 2025-10-29 | $188.50M derived: sum of 2 quarters · filed 2026-08-05 | $281.00M 10-Q · filed 2025-10-29 | $356.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $87.60M 10-Q · filed 2026-08-05 | $180.10M 10-Q · filed 2026-08-05 | $256.00M derived: sum of 3 quarters · filed 2026-08-05 | $339.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $92.50M 10-Q · filed 2026-05-06 | $168.40M derived: sum of 2 quarters · filed 2026-05-06 | $251.50M derived: sum of 3 quarters · filed 2026-05-06 | $329.30M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $75.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $159.00M derived: sum of 2 quarters · filed 2026-02-25 | $236.80M derived: sum of 3 quarters · filed 2026-02-25 | $309.70M 10-K · filed 2026-02-25 |
| 2024-09-30 | $83.10M 10-Q · filed 2025-10-29 | $160.90M derived: sum of 2 quarters · filed 2025-10-29 | $233.80M 10-Q · filed 2025-10-29 | $304.80M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $77.80M 10-Q · filed 2025-07-30 | $150.70M 10-Q · filed 2025-07-30 | $221.70M derived: sum of 3 quarters · filed 2026-02-25 | $291.80M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $72.90M 10-Q · filed 2025-04-30 | $143.90M derived: sum of 2 quarters · filed 2026-02-25 | $214.00M derived: sum of 3 quarters · filed 2026-02-25 | $278.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $71.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $141.10M derived: sum of 2 quarters · filed 2026-02-25 | $205.20M derived: sum of 3 quarters · filed 2026-02-25 | $257.50M 10-K · filed 2026-02-25 |
| 2023-09-30 | $70.10M 10-Q · filed 2024-10-30 | $134.20M derived: sum of 2 quarters · filed 2024-10-30 | $186.50M 10-Q · filed 2024-10-30 | $245.30M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $64.10M 10-Q · filed 2024-07-31 | $116.40M 10-Q · filed 2024-07-31 | $175.20M derived: sum of 3 quarters · filed 2025-02-26 | $212.40M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $52.30M 10-Q · filed 2024-05-01 | $111.10M derived: sum of 2 quarters · filed 2025-02-26 | $148.30M derived: sum of 3 quarters · filed 2025-02-26 | $178.00M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $58.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $96.00M derived: sum of 2 quarters · filed 2025-02-26 | $125.70M derived: sum of 3 quarters · filed 2025-02-26 | $151.60M 10-K · filed 2025-02-26 |
| 2022-09-30 | $37.20M 10-Q · filed 2023-11-01 | $66.90M derived: sum of 2 quarters · filed 2023-11-01 | $92.80M 10-Q · filed 2023-11-01 | $127.40M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $29.70M 10-Q · filed 2023-08-02 | $55.60M 10-Q · filed 2023-08-02 | $90.20M derived: sum of 3 quarters · filed 2024-02-21 | $117.90M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $25.90M 10-Q · filed 2023-05-03 | $60.50M derived: sum of 2 quarters · filed 2024-02-21 | $88.20M derived: sum of 3 quarters · filed 2024-02-21 | $125.40M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $34.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $62.30M derived: sum of 2 quarters · filed 2024-02-21 | $99.50M derived: sum of 3 quarters · filed 2024-02-21 | $122.50M 10-K · filed 2024-02-21 |
| 2021-09-30 | $27.70M 10-Q · filed 2022-11-02 | $64.90M derived: sum of 2 quarters · filed 2022-11-02 | $87.90M 10-Q · filed 2022-11-02 | $122.70M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $37.20M 10-Q · filed 2022-08-03 | $60.20M 10-Q · filed 2022-08-03 | $95.00M derived: sum of 3 quarters · filed 2023-02-22 | $119.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $23.00M 10-Q · filed 2022-05-04 | $57.80M derived: sum of 2 quarters · filed 2023-02-22 | $81.80M derived: sum of 3 quarters · filed 2023-02-22 | $107.70M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $34.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $58.80M derived: sum of 2 quarters · filed 2023-02-22 | $84.70M derived: sum of 3 quarters · filed 2023-02-22 | $108.10M 10-K · filed 2023-02-22 |
| 2020-09-30 | $24.00M 10-Q · filed 2021-11-03 | $49.90M derived: sum of 2 quarters · filed 2021-11-03 | $73.30M 10-Q · filed 2021-11-03 | $102.10M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $25.90M 10-Q · filed 2021-08-04 | $49.30M 10-Q · filed 2021-08-04 | $78.10M derived: sum of 3 quarters · filed 2021-08-04 | $111.10M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $23.40M 10-Q · filed 2021-05-05 | $52.20M derived: sum of 2 quarters · filed 2021-05-05 | $85.20M derived: sum of 3 quarters · filed 2021-05-05 | $111.90M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $28.80M 10-K · filed 2020-02-26 | $61.80M derived: sum of 2 quarters · filed 2020-10-28 | $88.50M derived: sum of 3 quarters · filed 2020-10-28 | $117.60M 10-K · filed 2022-02-24 |
| 2019-09-30 | $33.00M 10-Q · filed 2020-10-28 | $59.70M derived: sum of 2 quarters · filed 2020-10-28 | $88.80M 10-Q · filed 2020-10-28 | $120.70M derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-06-30 | $26.70M 10-Q · filed 2020-07-29 | $55.80M 10-Q · filed 2020-07-29 | $87.70M derived: sum of 3 quarters · filed 2020-07-29 | $139.60M derived: sum of 4 quarters · filed 2020-07-29 |
| 2019-03-31 | $29.10M 10-Q · filed 2020-04-29 | $61.00M derived: sum of 2 quarters · filed 2020-04-29 | $112.90M derived: sum of 3 quarters · filed 2020-04-29 | $174.60M derived: sum of 4 quarters · filed 2020-04-29 |
| 2018-12-31 | $31.90M 10-K · filed 2020-02-26 | $83.80M derived: sum of 2 quarters · filed 2020-02-26 | $145.50M derived: sum of 3 quarters · filed 2020-02-26 | $198.70M 10-K · filed 2021-02-24 |
| 2018-09-30 | $51.90M 10-K · filed 2020-02-26 | $113.60M derived: sum of 2 quarters · filed 2020-02-26 | $166.80M 10-Q · filed 2019-10-30 | $219.80M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $61.70M 10-K · filed 2020-02-26 | $114.90M 10-Q · filed 2019-07-31 | $167.90M derived: sum of 3 quarters · filed 2020-02-26 | $187.40M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $53.20M 10-K · filed 2020-02-26 | $106.20M derived: sum of 2 quarters · filed 2020-02-26 | $125.70M derived: sum of 3 quarters · filed 2020-02-26 | $144.60M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $53.00M 10-K · filed 2019-02-27 | $72.50M derived: sum of 2 quarters · filed 2019-02-27 | $91.40M derived: sum of 3 quarters · filed 2019-02-27 | $105.70M 10-K · filed 2020-02-26 |
| 2017-09-30 | $19.50M 10-K · filed 2019-02-27 | $38.40M derived: sum of 2 quarters · filed 2019-02-27 | $52.70M 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $18.90M 10-K · filed 2019-02-27 | $33.20M 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | $14.30M 10-K · filed 2019-02-27 | |||
| 2016-12-31 | $72.70M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |